亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study

医学 肝细胞癌 危险系数 索拉非尼 伦瓦提尼 临床终点 胃肠病学 内科学 随机对照试验 泌尿科 比例危险模型 外科 置信区间
作者
Xiaoyan Ding,Wei Sun,Wei Li,Yanjun Shen,Xiaodi Guo,Ying Teng,Xiaomin Liu,Linlin Zheng,Wendong Li,Jinglong Chen
出处
期刊:Cancer [Wiley]
卷期号:127 (20): 3782-3793 被引量:142
标识
DOI:10.1002/cncr.33677
摘要

BACKGROUND: The efficacy and safety of transarterial chemoembolization (TACE) plus lenvatinib in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) have not been evaluated. METHODS: In this open-label, single-center, randomized trial (ClinicalTrials.gov identifier: NCT04127396), participants with previously untreated HCC and type I-IV PVTT were randomized 1:1 to receive TACE plus lenvatinib (arm L; orally once daily, 12 mg for body weight ≥60 kg or 8 mg for body weight <60 kg) or TACE plus sorafenib (arm S; 400 mg orally twice daily in 28-day cycles). The primary end point was time-to-progression (TTP; time from randomization to disease progression) and secondary end points included objective response rate and toxicity. Prognostic factors were evaluated using a multivariable Cox proportional hazards model. RESULTS: Between December 30, 2018 and May 31, 2020, 64 patients were randomized (arm L, n = 32; arm S, n = 32); most patients had type I/II PVTT (71.9%), and the median target tumor diameter was 9.8 cm (range, 3.8-21.8). After a median follow-up of 16.1 months, patients in arm L had a higher median TTP (4.7 vs 3.1 months; hazard ratio [HR], 0.55; 95% CI, 0.32-0.95; P = .029) and objective response rate (53.1% vs 25.0%, P = .039) versus arm S. Multivariable analysis showed that TACE plus lenvatinib was significantly associated with higher TTP versus TACE plus sorafenib (HR, 0.50; 95% CI, 0.28-0.90; P = .021). Comparable safety profiles were observed in arms L and S. CONCLUSIONS: TACE plus lenvatinib was safe, well tolerated, and had favorable efficacy versus TACE plus sorafenib in patients with advanced HCC with PVTT and large tumor burden. LAY SUMMARY: Hepatocellular carcinoma with portal vein tumor thrombus has a poor prognosis. In addition, most phase 3 trials of drugs for hepatocellular carcinoma exclude patients with major portal vein invasion, and treatment options for these patients are limited. Transarterial chemoembolization has shown promising efficacy in these patients, especially in combination with systemic treatment or radiotherapy. However, transarterial chemoembolization plus lenvatinib has not been investigated in this setting. This open-label, single-center, randomized trial showed that transarterial chemoembolization plus lenvatinib is safe, well tolerated, and has favorable efficacy versus transarterial chemoembolization plus sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombus.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_LMo56Z完成签到,获得积分10
2秒前
呆萌访琴完成签到,获得积分10
3秒前
18秒前
幸福海之完成签到,获得积分10
34秒前
盐水菠萝发布了新的文献求助10
38秒前
1分钟前
Junex完成签到,获得积分10
1分钟前
无限寒珊完成签到,获得积分10
1分钟前
欣喜寒烟发布了新的文献求助10
1分钟前
标致的忆梅完成签到,获得积分10
1分钟前
1分钟前
灵剑山发布了新的文献求助10
1分钟前
研友_nxw2xL完成签到,获得积分0
1分钟前
充电宝的应助被科研通管家采纳,获得10
1分钟前
香蕉觅云的应助被科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
细心慕凝发布了新的文献求助10
1分钟前
欣喜香菇发布了新的文献求助10
1分钟前
Ava的应助被欣喜香菇采纳,获得10
2分钟前
Bowman完成签到,获得积分0
2分钟前
如意紫翠完成签到,获得积分10
2分钟前
细心慕凝完成签到,获得积分10
2分钟前
LHY完成签到,获得积分10
2分钟前
2分钟前
香蕉乐曲完成签到,获得积分10
3分钟前
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
沉静的愫完成签到,获得积分10
3分钟前
4分钟前
ww完成签到,获得积分10
4分钟前
ww发布了新的文献求助10
4分钟前
4分钟前
adgn发布了新的文献求助10
4分钟前
老实的石头完成签到,获得积分10
4分钟前
5分钟前
个性鹭洋完成签到,获得积分10
5分钟前
丘比特的应助被adgn采纳,获得10
5分钟前
5分钟前
戴肉肉完成签到 ,获得积分10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173069
求助须知:如何正确求助?哪些是违规求助? 9565519
关于积分的说明 21780383
捐赠科研通 7765085
什么是DOI,文献DOI怎么找? 3431528
关于科研通互助平台的介绍 2555638
邀请新用户注册赠送积分活动 2476668